CU20110223A7 - Lipopolisacárido de ochrobactrum intermedium y su uso como inmunoestimulante en mamíferos - Google Patents

Lipopolisacárido de ochrobactrum intermedium y su uso como inmunoestimulante en mamíferos

Info

Publication number
CU20110223A7
CU20110223A7 CU20110223A CU20110223A CU20110223A7 CU 20110223 A7 CU20110223 A7 CU 20110223A7 CU 20110223 A CU20110223 A CU 20110223A CU 20110223 A CU20110223 A CU 20110223A CU 20110223 A7 CU20110223 A7 CU 20110223A7
Authority
CU
Cuba
Prior art keywords
immunostimulant
mammals
lipopolisacárido
ochrobactrum intermedium
ochrobactrum
Prior art date
Application number
CU20110223A
Other languages
English (en)
Other versions
CU24041B1 (es
Inventor
Escudero Manuel Fresno
Guisasola Juan Ignacio Ovejero
Original Assignee
Ovejero S A Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovejero S A Lab filed Critical Ovejero S A Lab
Publication of CU20110223A7 publication Critical patent/CU20110223A7/es
Publication of CU24041B1 publication Critical patent/CU24041B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al aislamiento, purificación y caracterización del lipopolisacárido (LPS) de la cepa Ochrobactrum intermedium LMG3306, y su uso como inmunoestimulante en mamíferos, el procedimiento para la preparación de un compuesto farmacéutico para el tratamiento y/o la prevención de la sepsis y un adyuvante para unavacuna en animales inmumodeprimidos y contra la Leishmania.
CU2011000223A 2009-06-04 2011-12-02 Procedimiento de preparación del lipopolisacárido de ochrobactrum intermedium lmg3306 y la composición que lo contiene CU24041B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200930265A ES2352780B2 (es) 2009-06-04 2009-06-04 Lipopolisacárido de ochrobactrum intermedium contra la sepsis.
PCT/EP2009/009342 WO2010139352A1 (en) 2009-06-04 2009-12-31 Lipopolysaccharide of ochrobactrum intermedium and their use as immunostimulant of mammalians

Publications (2)

Publication Number Publication Date
CU20110223A7 true CU20110223A7 (es) 2012-06-21
CU24041B1 CU24041B1 (es) 2014-11-27

Family

ID=41796455

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000223A CU24041B1 (es) 2009-06-04 2011-12-02 Procedimiento de preparación del lipopolisacárido de ochrobactrum intermedium lmg3306 y la composición que lo contiene

Country Status (20)

Country Link
US (1) US9241954B2 (es)
EP (1) EP2437754B1 (es)
JP (1) JP5730862B2 (es)
KR (1) KR20120061045A (es)
CN (1) CN102802639A (es)
AU (1) AU2009347459A1 (es)
BR (1) BRPI0924393A2 (es)
CA (1) CA2763266A1 (es)
CL (1) CL2011003033A1 (es)
CO (1) CO6470857A2 (es)
CU (1) CU24041B1 (es)
EA (1) EA025766B1 (es)
ES (2) ES2352780B2 (es)
IL (1) IL216560A0 (es)
MX (1) MX2011012934A (es)
NZ (1) NZ596599A (es)
PL (1) PL2437754T3 (es)
SG (1) SG176660A1 (es)
WO (1) WO2010139352A1 (es)
ZA (1) ZA201200021B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103937722B (zh) * 2014-04-24 2016-10-26 烟台地元生物科技有限公司 中间苍白杆菌及微生物菌剂和它们的应用
CN106754562B (zh) * 2017-02-14 2020-06-02 南京中医药大学 一种高产细菌多糖的菌株及其发酵中药废弃物制备多糖的方法
CN106755186B (zh) * 2017-02-14 2020-03-31 南京中医药大学 一种中间苍白杆菌胞外多糖及其在土壤改良方面的应用
CN109182159B (zh) * 2018-07-27 2021-04-23 华南农业大学 一种n-酰基高丝氨酸内酯淬灭菌及其在病害防控中的应用
WO2020227159A2 (en) * 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
CN111053789A (zh) * 2019-11-26 2020-04-24 湖南营养树生物科技有限公司 调节免疫系统的方法和组合物
RU2736933C1 (ru) * 2020-05-20 2020-11-23 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени Г.П. Сомова" (НИИ эпидемиологии и микробиологии имени Г.П. Сомова) Адъювант
CN111909874B (zh) * 2020-08-17 2022-08-19 东北农业大学 一株生防菌i-5及其在防治紫花苜蓿根腐病中的应用
CN112625943B (zh) * 2020-12-02 2021-11-16 安徽农业大学 一种玉米用溶钾菌剂及其制备方法和应用
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
WO2024159198A2 (en) * 2023-01-27 2024-08-02 Nagy Aurangzeb Nafees Compositions and methods using tetrahydrocannabinol and compositions including same for treating indications involving inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824310A (en) * 1991-10-22 1998-10-20 The United States Of America As Represented By The Department Of Health And Human Services Lipopplysaccharide conjugate vaccines
GB9706930D0 (en) 1997-04-04 1997-05-21 Univ Glasgow Leishmania vaccine
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2009012166A1 (en) * 2007-07-13 2009-01-22 Infectious Disease Research Institute Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis

Also Published As

Publication number Publication date
IL216560A0 (en) 2012-02-29
AU2009347459A1 (en) 2011-12-22
KR20120061045A (ko) 2012-06-12
EA201190309A1 (ru) 2012-05-30
US20120107352A1 (en) 2012-05-03
ZA201200021B (en) 2013-03-27
CN102802639A (zh) 2012-11-28
CA2763266A1 (en) 2010-12-09
BRPI0924393A2 (pt) 2016-09-06
US9241954B2 (en) 2016-01-26
ES2352780B2 (es) 2011-09-15
ES2653202T3 (es) 2018-02-06
SG176660A1 (en) 2012-01-30
CU24041B1 (es) 2014-11-27
WO2010139352A1 (en) 2010-12-09
EA025766B1 (ru) 2017-01-30
NZ596599A (en) 2013-08-30
EP2437754B1 (en) 2017-09-20
MX2011012934A (es) 2012-04-30
CL2011003033A1 (es) 2012-07-06
PL2437754T3 (pl) 2018-03-30
ES2352780A1 (es) 2011-02-23
CO6470857A2 (es) 2012-06-29
JP2012528805A (ja) 2012-11-15
EP2437754A1 (en) 2012-04-11
JP5730862B2 (ja) 2015-06-10

Similar Documents

Publication Publication Date Title
CU20110223A7 (es) Lipopolisacárido de ochrobactrum intermedium y su uso como inmunoestimulante en mamíferos
EA201001820A1 (ru) Новые иммуноадъювантные соединения на основе флагеллина и их применение
CR20120025A (es) Antigenos de virus de sincicio respiratorio recombinantes
CL2014000630A1 (es) Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc.
UY32571A (es) Compuestos derivados de pirazol amida
CO6551750A2 (es) Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio
UY31942A (es) Formulaciones de adyuvante comprendiendo combinaciones de triterpenoides, esteroles, inmunomoduladores, polímeros y estimuladores de th2, procedimientos de preparación, composiciones y aplicaciones.
MX2011003843A (es) Incorporacion de adyuvante en inmunonanoterapeuticos.
MX381488B (es) Indoles para su uso en la infección por el virus de la gripe.
MY178905A (en) Prevention, treatment and diagnosis of p.gingivalis infection
MX2011003756A (es) Composicion de vacuna para uso contra influenza.
BRPI1005670A8 (pt) composições adjuvantes e processos de uso.
DK2133420T3 (da) Fremgangsmåde til fremstilling af L-aminosyrer under anvendelse af forbedrede stammer af familien Enterobacteriaceae
MX2012001495A (es) Polipeptidos de porphyromonas gingivalis.
WO2011003965A3 (fr) Dispositif de séparation linéaire douce d'une première pièce et d'une seconde pièce
CL2017000232A1 (es) Cepas de salmonella gallinarum modificadas avirulentas; composición farmacéutica que la usan; aditivo para piensos; procedimiento de tratamiento de la tifosis aviar infecciosa por salmonellla gallinarum. (divisional solicitud 3285-2013)
CL2012002954A1 (es) Compuestos derivados de heterobiaril-ciclohexil-tetraazabenzo[e]azules sustituidos, modulares del receptor de vasopresina v1a; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o el tratamient5o de la dismenorrea, disfuncion sexual masculina o femenina, ansiedad, hipertension, entre otros.
ES2415029R1 (es) Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.
MX338441B (es) Uso de 2,3-dihidroxipropil dodecanoato para tratar seborrea.
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
MX2009008767A (es) Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacuna anti-gripal.
EA201290319A1 (ru) Применение источника l3 и/или l5 в качестве вакцины или диагностического средства для паразитарного заболевания
EA201171142A1 (ru) Таблетки ретигабина предпочтительно с модифицированным высвобождением
MX349944B (es) Lactobacillus brevis productor de reuterina.
BR112012007577A2 (pt) semigéis de ácido silícico de superfície modificada

Legal Events

Date Code Title Description
FG Grant of patent